EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC 4.0

Mitigating off‐target effects of small RNAs: conventional approaches, network theory and artificial intelligence

Zoltán Bereczki, Bettina Benczik, Olivér M Balogh, Szandra Marton, Eszter Puhl, Mátyás Pétervári, Máté Váczy-Földi, Zsolt Tamás Papp, András Makkos, Kimberly Glass, Fabian Locquet, Gerhild Euler and 3 more

British Journal of Pharmacology · 2025-01 · 182 (2) · 340-379

DOI: 10.1111/bph.17302 ↗

At a glance

Übersichtsarbeit in British Journal of Pharmacology, published online on 2024-09-18. Written by Zoltán Bereczki and 14 co-authors. Institution: Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary. Major MEDLINE topics: Artificial Intelligence. Cited 84 times so far (Crossref); 332 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: HUN-REN Hungarian Research Network, Ministry for Innovation and Technology in Hungary, European Commission.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Three types of highly promising small RNA therapeutics, namely, small interfering RNAs (siRNAs), microRNAs (miRNAs) and the RNA subtype of antisense oligonucleotides (ASOs), offer advantages over small‐molecule drugs. These small RNAs can target any gene product, opening up new avenues of effective and safe therapeutic approaches for a wide range of diseases. In preclinical research, synthetic small RNAs play an essential role in the investigation of physiological and pathological pathways as silencers of specific genes, facilitating discovery and validation of drug targets in different conditions. Off‐target effects of small RNAs, however, could make it difficult to interpret experimental results in the preclinical phase and may contribute to adverse events of small RNA therapeutics. Out of the two major types of off‐target effects we focused on the hybridization‐dependent, especially on the miRNA‐like off‐target effects. Our main aim was to discuss several approaches, including sequence design, chemical modifications and target prediction, to reduce hybridization‐dependent off‐target effects that should be considered even at the early development phase of small RNA therapy. Because there is no standard way of predicting hybridization‐dependent off‐target effects, this review provides an overview of all major state‐of‐the‐art computational methods and proposes new approaches, such as the possible inclusion of network theory and artificial intelligence (AI) in the prediction workflows. Case studies and a concise survey of experimental methods for validating in silico predictions are also presented. These methods could contribute to interpret experimental results, to minimize off‐target effects and hopefully to avoid off‐target‐related adverse events of small RNA therapeutics. LINKED ARTICLES This article is part of a themed issue Non‐coding RNA Therapeutics. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v182.2/issuetoc

Subjects

MeSH terms (MEDLINE)

Artificial IntelligenceHumansAnimalsMicroRNAsRNA, Small InterferingOligonucleotides, Antisense

Author keywords

bioinformaticsceRNA networkchemical modificationsfunctional analysismachine learningneural networkpost‐transcriptional regulationrisk minimizationtarget identification

Substances

MicroRNAsRNA, Small InterferingOligonucleotides, Antisense

Authors and institutions

  • Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary.
  • Center for Pharmacology and Drug Research & Development, Semmelweis University, Budapest, Hungary.
  • HUN-REN-SU System Pharmacology Research Group, Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary.
  • Pharmahungary Group, Szeged, Hungary.
  • Sanovigado Kft, Budapest, Hungary.
  • Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.

ORCID profiles: Bence Ágg

Funding

  • HUN-REN Hungarian Research Network
  • Ministry for Innovation and Technology in Hungary
  • European Commission
  • Nemzeti Kutatási, Fejlesztési és Innovációs Alap
  • National Research, Development and Innovation Office of Hungary
  • Semmelweis 250+ Excellence Fellowship
  • New National Excellence Program of the Ministry for Culture and Innovation
  • National Heart, Lung and Blood Institute

Cite

APA

Bereczki, Z., Benczik, B., Balogh, O. M., Marton, S., Puhl, E., Pétervári, M., Váczy-Földi, M., Papp, Z. T., Makkos, A., Glass, K., Locquet, F., Euler, G., Schulz, R., Ferdinandy, P., & Ágg, B. (2025). Mitigating off‐target effects of small RNAs: conventional approaches, network theory and artificial intelligence. British Journal of Pharmacology, 182(2), 340-379. https://doi.org/10.1111/bph.17302

Vancouver

Bereczki Z, Benczik B, Balogh OM, Marton S, Puhl E, Pétervári M, et al. Mitigating off‐target effects of small RNAs: conventional approaches, network theory and artificial intelligence. British Journal of Pharmacology. 2025;182(2):340-379. doi:10.1111/bph.17302

BibTeX
@article{Bereczki2025,
  author = {Bereczki, Zoltán and Benczik, Bettina and Balogh, Olivér M and Marton, Szandra and Puhl, Eszter and Pétervári, Mátyás and Váczy-Földi, Máté and Papp, Zsolt Tamás and Makkos, András and Glass, Kimberly and Locquet, Fabian and Euler, Gerhild and Schulz, Rainer and Ferdinandy, Péter and Ágg, Bence},
  title = {Mitigating off‐target effects of small RNAs: conventional approaches, network theory and artificial intelligence},
  journal = {British Journal of Pharmacology},
  year = {2025},
  volume = {182},
  number = {2},
  pages = {340--379},
  doi = {10.1111/bph.17302}
}
Start for free →